Influvac

Influenza Virus B/Austria/1359417/2021-like strain (B/Austria/1359417/2021, Bvr-26) and Influenza A/Vic, the active ingredients in Influvac, are inactivated influenza virus vaccines presented as a multi‑strain injectable for intramuscular or subcutaneous use. They stimulate immunity to prevent seasonal influenza caused by the included B and A strains in adults and children.

GNH USA supplies Influvac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory support for global distribution. Its logistics network ensures timely delivery in compliance with cold‑chain requirements.

Influvac is used to prevent influenza infection by targeting the seasonal influenza virus strains included in the vaccine. - Seasonal influenza (B/Austria/1359417/2021-like strain): Provides immunity that reduces the risk of illness caused by the matched influenza B strain. - Seasonal influenza (Influenza A/Vic strain): Induces protective antibodies against the A/Vic virus, decreasing infection rates. - General influenza prevention: Helps lower overall community transmission of the circulating influenza viruses covered by the formulation.

Like all vaccines, Influvac may be associated with local and systemic reactions.

Common Side Effects: - Injection site pain: mild to moderate soreness at the site of administration. - Redness or swelling: transient erythema or edema around the injection. - Low‑grade fever: temperature rise up to 38 °C within 24 hours. - Headache: mild headache lasting a day or two. - Myalgia: muscle aches commonly reported after vaccination.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder reported post‑vaccination. - Seizures: infrequent occurrence, especially in children with fever. - Thrombocytopenia: low platelet count observed in isolated cases.

Before administering Influvac, healthcare professionals should consider the following precautions. - Allergy assessment: avoid use in individuals with severe hypersensitivity to any vaccine component. - Previous reaction: postpone vaccination if the patient experienced a serious reaction to a prior influenza vaccine. - Acute illness: defer vaccination until recovery from moderate or severe febrile illness. - Immunocompromised patients: vaccine may be less immunogenic; assess benefit‑risk individually. - Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Influvac may interact with other agents; relevant interactions are categorized below.

Major Interactions (Avoid): - Live attenuated vaccines: avoid simultaneous administration; separate by at least 4 weeks to prevent interference. - Immunoglobulin therapy: concurrent use may reduce vaccine efficacy; schedule at least 2 weeks apart.

Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen, ibuprofen): may blunt antibody response if given prophylactically; use only for symptomatic relief. - Immunosuppressive drugs (e.g., corticosteroids, biologics): may diminish immune response; monitor seroconversion. - Egg‑based vaccine production: individuals with severe egg allergy should be evaluated, although most modern formulations are low‑egg.